ATE414542T1 - Nsaid zusammensetzungen enthaltend lecithinöl zum schutz des magen-darm-traktes und zur erhöhten therapeutischen wirkung - Google Patents

Nsaid zusammensetzungen enthaltend lecithinöl zum schutz des magen-darm-traktes und zur erhöhten therapeutischen wirkung

Info

Publication number
ATE414542T1
ATE414542T1 AT01273758T AT01273758T ATE414542T1 AT E414542 T1 ATE414542 T1 AT E414542T1 AT 01273758 T AT01273758 T AT 01273758T AT 01273758 T AT01273758 T AT 01273758T AT E414542 T1 ATE414542 T1 AT E414542T1
Authority
AT
Austria
Prior art keywords
protection
therapeutic effect
compositions containing
gastrointestinal tract
increased therapeutic
Prior art date
Application number
AT01273758T
Other languages
English (en)
Inventor
Lenard Lichtenberger
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE414542T1 publication Critical patent/ATE414542T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01273758T 2000-12-19 2001-12-19 Nsaid zusammensetzungen enthaltend lecithinöl zum schutz des magen-darm-traktes und zur erhöhten therapeutischen wirkung ATE414542T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25671100P 2000-12-19 2000-12-19

Publications (1)

Publication Number Publication Date
ATE414542T1 true ATE414542T1 (de) 2008-12-15

Family

ID=22973287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01273758T ATE414542T1 (de) 2000-12-19 2001-12-19 Nsaid zusammensetzungen enthaltend lecithinöl zum schutz des magen-darm-traktes und zur erhöhten therapeutischen wirkung

Country Status (17)

Country Link
EP (1) EP1343529B1 (de)
JP (2) JP4958381B2 (de)
KR (1) KR100884493B1 (de)
CN (2) CN102258457B (de)
AT (1) ATE414542T1 (de)
AU (1) AU2001297778B2 (de)
BR (1) BR0116380A (de)
CA (1) CA2431606C (de)
CY (1) CY1110474T1 (de)
DE (1) DE60136647D1 (de)
DK (1) DK1343529T3 (de)
ES (1) ES2317873T3 (de)
IL (2) IL156361A0 (de)
MX (1) MXPA03005550A (de)
PT (1) PT1343529E (de)
SI (1) SI1343529T1 (de)
WO (1) WO2002085414A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653975A4 (de) * 2003-07-31 2006-10-25 Univ Texas Zusammensetzungen und verfahren zur behandlung, prävention und/oder linderung von krebs, dem einsetzen von krebs oder der symptome von krebs
US20050176809A1 (en) * 2004-02-05 2005-08-11 Rodlen Laboratories, Inc. Method and compositions for treatment of painful disorders
WO2005084683A1 (fr) * 2004-03-03 2005-09-15 MARTINS, José, Araujo Composition a base de lecithine vegetale, ex. de soja, vitamines du complexe b et d'acide acetylsalicylique, et son utilisation pour la fabrication d'un medicament pour le traitement des maladies neuro-degeneratives
KR20070063587A (ko) * 2004-10-12 2007-06-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 정제된 인지질-비스테로이드성 소염 약물 연합 조성물 및이의 제조방법 및 사용방법
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
CA2657769C (en) 2006-07-19 2014-11-18 The Board Of Regents Of The University Of Texas System Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
WO2009039505A1 (en) * 2007-09-20 2009-03-26 Rutgers, The State University Of New Jersey Compositions and methods for treating cardiovascular conditions
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
EP2629779B1 (de) * 2010-10-22 2017-06-21 Dr. Reddy's Laboratories SA. Verwendung eines lagerstabilen viskösen phospholipid-depots zur wundbehandlung
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2013022410A2 (en) 2011-08-08 2013-02-14 Mahmut Bilgic Production method for effervescent formulations comprising dexketoprofen
WO2013049749A2 (en) 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
US10286093B2 (en) * 2013-05-23 2019-05-14 Neurosn, Inc. Method of diagnosing and treating Alzheimer's disease
US9446056B2 (en) * 2014-02-11 2016-09-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
CN103908454B (zh) * 2014-04-17 2016-08-24 兆科药业（广州）有限公司 一种药物组合物及其制备方法和应用
WO2016094617A1 (en) * 2014-12-11 2016-06-16 Phosphorex, Inc. Aqueous topical drug formulation with controlled release and increased stability
CN104739843A (zh) * 2015-04-15 2015-07-01 郭志标 一种用于治疗口腔溃疡的药物组合物
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN108542909B (zh) * 2018-03-30 2020-07-07 浙江海昶生物医药技术有限公司 一种阿司匹林磷脂固化组合物、其制备方法及药物制剂
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
KR20220158031A (ko) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
CN120643509B (zh) * 2025-08-18 2025-12-05 杭州市滨江区浙医二院经血管植入器械研究院 血管内长效留存的油相药物溶液及液体灌注球囊传递方式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
US5154930A (en) 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH07503952A (ja) * 1992-02-12 1995-04-27 ジヤンセン・シラグ・ソチエタ・ペル・アチオニ リポソームピロキシカム組成物
EP1214940B1 (de) * 1995-01-27 2009-03-11 Board of Regents, The University of Texas System Methoden zur Erhöhung der Wirksamkeit von nicht-steroidalen antientzündlichen Arzneien und dazu verwendbare Zusammensetzungen enthaltend zwitterionische Phospholipide
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein

Also Published As

Publication number Publication date
HK1161107A1 (en) 2012-08-24
KR20030072565A (ko) 2003-09-15
EP1343529A2 (de) 2003-09-17
AU2001297778C1 (en) 2002-11-05
CA2431606A1 (en) 2002-10-31
CN102258457A (zh) 2011-11-30
IL156361A0 (en) 2004-01-04
MXPA03005550A (es) 2004-05-14
JP2005506303A (ja) 2005-03-03
JP4958381B2 (ja) 2012-06-20
IL156361A (en) 2011-04-28
PT1343529E (pt) 2009-02-27
DE60136647D1 (de) 2009-01-02
WO2002085414A2 (en) 2002-10-31
KR100884493B1 (ko) 2009-02-18
ES2317873T3 (es) 2009-05-01
CY1110474T1 (el) 2015-04-29
WO2002085414A3 (en) 2003-05-08
AU2001297778B2 (en) 2007-05-31
CA2431606C (en) 2011-07-19
EP1343529B1 (de) 2008-11-19
CN1543358A (zh) 2004-11-03
JP2010031044A (ja) 2010-02-12
CN102258457B (zh) 2015-07-01
DK1343529T3 (da) 2009-03-16
BR0116380A (pt) 2005-04-05
SI1343529T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
DE60136647D1 (de) Nsaid zusammensetzungen enthaltend lecithinöl zum schutz des magen-darm-traktes und zur erhöhten therapeutischen wirkung
ES2605405T3 (es) Composiciones que contienen agentes antiacné y su uso
JP6228540B2 (ja) Ｔｒｐｖ１選択的アゴニストを含む疼痛軽減組成物、ならびにその製造および使用
US10874689B2 (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
AU2023222925B2 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
EA200801492A1 (ru) Фармацевтическое применение замещенных амидов
US20250099498A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
US9480704B2 (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
US20170157169A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
CA2958169C (en) Strontium-based compositions and formulations for pain, itching, and inflammation
US8975298B2 (en) Therapeutic agent for pain
RU2705200C1 (ru) Спрей для профилактики инфекционно-респираторных заболеваний
FR2860720A1 (fr) Nouvelles compositions pharmaceutiques pour traiter la xerostomie et maladies similaires
JPS6322518A (ja) Ｎ−（２，６−ジクロル−ｍ−トリル）アントラニル酸含有のゲル状製薬組成物
TH4847C3 (th) สารผสมทางเภสัชกรรมสำหรับบำบัดอาการปวด
TH4847A3 (th) สารผสมทางเภสัชกรรมสำหรับบำบัดอาการปวด
JP2019501221A (ja) 末梢関節、脊椎関節および／または結合組織の細胞外マトリックス構成要素の処置のための製剤、製造方法および使用
HK1204266B (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
WO2015114194A1 (es) Composición de azufre liposomado

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1343529

Country of ref document: EP